Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM4YMIS)

Drug Name
Aldesleukin Drug Info
Synonyms Proleukin (TN)
Indication
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [1]
Childhood myelodysplastic syndrome Approved [2]
Cutaneous melanoma 2C30 Approved [3]
Desmoplastic small round cell tumor Approved [2]
Leukemia Approved [1]
Lung cancer 2C25.0 Approved [4]
Renal cell carcinoma 2C90 Approved [5]
Non-hodgkin lymphoma 2B33.5 Phase 2 [5]
Colon cancer 2B90.Z Investigative [6]
Gastric cancer 2B72 Investigative [2]
Therapeutic Class
Anticancer Agents
Cross-matching ID
TTD Drug ID
DM4YMIS

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-2 (IL2) TTF89GD IL2_HUMAN Modulator [7]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin-2 (IL2) DTT IL2 0.848 4.548 3.548 4.053
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Acute myelogenous leukaemia
ICD Disease Classification 2A41
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-2 (IL2) DTT IL2 5.88E-01 0.13 0.59
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs. 1993 Sep;46(3):446-514.
2 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
3 Aldesleukin. 2018 May 5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012C.
4 Targeting interleukin-1 and inflammation in lung cancer. Biomark Res. 2022 Jan 27;10(1):5.
5 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
6 Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin Cancer Res. 2008 Jul 1;14(13):4192-9.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.